APA (7th ed.) Citation

Cros, S., Capdevila, L., Carcereny, E., Moran, T., Martinez, A., Buges, C., . . . Rosell, R. (2011). 1434 POSTER Impact of KRAS Mutations (Krasmut) on Clinical Outcome in Stage IV Non-small Cell Lung Cancer (NSCLC) Patients (pts) and Their Relationship With Other Biomarkers. European Journal of Cancer, 47, S179. https://doi.org/10.1016/S0959-8049(11)70927-3

Chicago Style (17th ed.) Citation

Cros, S., L. Capdevila, E. Carcereny, T. Moran, A. Martinez, C. Buges, N. Pardo, J.L Cuadra, and R. Rosell. "1434 POSTER Impact of KRAS Mutations (Krasmut) on Clinical Outcome in Stage IV Non-small Cell Lung Cancer (NSCLC) Patients (pts) and Their Relationship With Other Biomarkers." European Journal of Cancer 47 (2011): S179. https://doi.org/10.1016/S0959-8049(11)70927-3.

MLA (9th ed.) Citation

Cros, S., et al. "1434 POSTER Impact of KRAS Mutations (Krasmut) on Clinical Outcome in Stage IV Non-small Cell Lung Cancer (NSCLC) Patients (pts) and Their Relationship With Other Biomarkers." European Journal of Cancer, vol. 47, 2011, p. S179, https://doi.org/10.1016/S0959-8049(11)70927-3.